Magnesium compositions and uses thereof for neurological disorders
A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another condition of a subject, and/or cognitive, learning, and/or memory function. A magnesium-counter ion composition provided herein may be useful for administration to a subject presenting magnesium deficiency, mild cognitive impairment, Alzheimer's disease, attention deficit hyperactivity disorder, ALS, Parkinson's disease, diabetes, migraine, anxiety disorder, mood disorder, and/or hypertension. A kit, method, and other associated technology are also provided.
1. A method of ameliorating the effects of a neurological disorder comprising administering to a subject an amount of magnesium-containing compound effective to increase a physiological concentration of magnesium by at least about 5% as compared to an initial level of magnesium prior to said administration, wherein in the magnesium-containing compound comprises magnesium threonate.
2. The method of claim 1 , wherein said increase is measured under a fasting condition.
3. The method of claim 2 , wherein said concentration of magnesium is measured after fasting for at least about twelve hours.
4. The method of claim 1 , wherein said neurological disorder is dementia.
5. The method of claim 1 , wherein said neurological disorder is Alzheimer's disease.
6. The method of claim 1 , wherein said neurological disorder is depression.
7. The method of claim 1 , wherein said physiological concentration is serum concentration, plasma concentration, or cerebrospinal fluid concentration.
8. The method of claim 1 , wherein said magnesium threonate is a magnesium-counter ion complex.
9. The method of claim 1 , wherein said magnesium-containing compound is a magnesium-supplemented foodstuff.
10. The method of claim 1 , wherein said concentration is maintained for a period of greater than 4 months.
11. The method of claim 1 , further comprising the step of determining starting physiological magnesium concentration of said subject under a fasting condition.
12. A method of therapeutic or prophylactic treatment of neurological disorder, comprising:
administering to a subject in need of therapeutic or prophylactic treatment of said neurological disorder, a magnesium-containing composition to yield a sustained level of physiological concentration of magnesium of 0.75 mM or above for at least about 15 days, wherein the magnesium-containing composition comprises magnesium threonate.
13. The method of claim 12 , wherein the composition of magnesium yields a sustained level of physiological concentration of magnesium of 0.75 mM or above for at least about 1 month.
14. The method of claim 12 , wherein the composition of magnesium yields a sustained level of physiological concentration of magnesium of 0.75 mM or above for at least about 4 months.
15. The method of claim 12 , wherein said neurological disorder is dementia.
16. The method of claim 12 , wherein said neurological disorder is depression.
17. A method of therapeutic or prophylactic treatment of a neurological disorder comprising administering to a subject an amount of metal-organic counter ion complex effective to increase a physiological concentration of threonate by at least about 10% as compared to an initial level of threonate prior to said administration.
18. The method of claim 17 , wherein said metal-organic counter ion complex comprises threonate as a counter-ion.